title: Serum proteomic test in advanced non-squamous non-small cell lung cancer treated in first line with standard chemotherapy.
abstract: VeriStrat is a blood-based proteomic test with predictive and prognostic significance in second-line treatments for non-small cell lung cancer (NSCLC). This trial was designed to investigate the role of VeriStrat in first-line treatment of advanced NSCLC with standard chemotherapy. Here we present the results for 76 non-squamous patients treated with a combination of carboplatin or cisplatin with pemetrexed.
  
  
  
  The test-assigned classifications of VeriStrat Good or VeriStrat Poor to samples collected at baseline. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS) and objective response. Exploratory analyses of end points separately in carboplatin/pemetrexed and cisplatin/pemetrexed subgroups were also conducted.
  
  
  
  Patients classified as VeriStrat Good had longer PFS and OS than VeriStrat Poor: 6.5 vs 1.6 months and 10.8 vs 3.4 months, respectively; the corresponding hazard ratios (HRs) were 0.36 (P<0.0001) and 0.26 (P<0.0001); they were also more likely to achieve objective response. Prognostic significance of VeriStrat was confirmed in multivariate analysis. Significant differences in OS and PFS between Veristrat classifications were also found when treatment subgroups were analysed separately.
  
  
  
  The trial demonstrated clinical utility of VeriStrat as a prognostic test for standard first-line chemotherapy of non-squamous advanced NSCLC.
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Grossi
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Rijavec
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Genova
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Barletta
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Biello
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Maggioni
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Burrafato
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: C
authors.initials: C
authors.lastname: Sini
authors.affiliation: Lung Cancer Unit, IRCCS AOU San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Largo R. Benzi 10, 16132 Genova, Italy.
authors.forename: M G
authors.initials: MG
authors.lastname: Dal Bello
authors.affiliation: Biodesix, 2970 Wilderness Place, Boulder, CO 80301, USA.
authors.forename: K
authors.initials: K
authors.lastname: Meyer
authors.affiliation: Biodesix, 2970 Wilderness Place, Boulder, CO 80301, USA.
authors.forename: J
authors.initials: J
authors.lastname: Roder
authors.affiliation: Biodesix, 2970 Wilderness Place, Boulder, CO 80301, USA.
authors.forename: H
authors.initials: H
authors.lastname: Roder
authors.affiliation: Biodesix, 2970 Wilderness Place, Boulder, CO 80301, USA.
authors.forename: J
authors.initials: J
authors.lastname: Grigorieva
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001774:Blood Chemical Analysis / Q000379:methods*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D000068437:Pemetrexed / Q000008:administration & dosage / Q000009:adverse effects; D011237:Predictive Value of Tests; D011379:Prognosis; D040901:Proteomics; D059039:Standard of Care; D016019:Survival Analysis
chemical_list: D000068437:Pemetrexed; D016190:Carboplatin; D002945:Cisplatin